Commentary: Tackling corruption in the life sciences sector
This article was originally published in Scrip
What is the risk that business practices in life science companies might be found to be corrupt by enforcement agencies? Amy J Conway-Hatcher, Jürgen Beninca and Emma O’Kane of the US-based law firm Morgan Lewis describe some of the potential pitfalls for pharmaceutical executives.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.